Monoamine Oxidase Inhibitors - Pipeline Insight, 2024

This “Monoamine Oxidase Inhibitor (MAOIs) - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Monoamine Oxidase Inhibitor (MAOIs) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Monoamine Oxidase Inhibitor (MAOIs) Understanding

Monoamine Oxidase Inhibitor (MAOIs): Overview

Monoamine oxidase (MAO; EC 1.4.3.4.) is a widely distributed mitochondrial enzyme with high expression levels in gastro-intestinal and hepatic as well as neuronal tissues. There are two types of monoamine oxidase, A and B. The MOA A is mostly distributed in the placenta, gut, and liver, but MOA B is present in the brain, liver, and platelets.

Function - The enzyme catalyzes the oxidative deamination of a variety of monoamines, both endogenous and exogenous, and has major roles in metabolizing released neurotransmitters, and in detoxification of a large variety of endogenous and exogenous amines.

Monoamine Oxidase Inhibitor (MAOIs) - Monoamine Oxidase Inhibitor (MAOIs) are responsible for blocking the monoamine oxidase enzyme. The monoamine oxidase enzyme breaks down different types of neurotransmitters from the brain: norepinephrine, serotonin, dopamine, and tyramine. MAOIs inhibit the breakdown of these neurotransmitters thus, increasing their levels and allowing them to continue to influence the cells that have been affected by depression.

Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs Chapters

This segment of the Monoamine Oxidase Inhibitor (MAOIs) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Monoamine Oxidase Inhibitor (MAOIs) Emerging Drugs

Ladostigil: Avraham PharmaceuticalsLadostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders likeAlzheimer’s disease, Lewy body disease, and Parkinson’s disease. It acts as a reversible acetylcholinesterase andbutyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.

Safinamide: Newron PharmaceuticalsA selective monoamine oxidase B (MAO-B) inhibitor, which reduces the degradation of secreted dopamine, helping to maintain the density of dopamine in the brain. The drug is in phase 2 stage of development for the treatment of Drug-induced dyskinesia.

Monoamine Oxidase Inhibitor (MAOIs): Therapeutic Assessment

This segment of the report provides insights about the different Monoamine Oxidase Inhibitor (MAOIs) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Monoamine Oxidase Inhibitor (MAOIs)

There are approx. 7+ key companies which are developing the Monoamine Oxidase Inhibitor (MAOIs). The companies which have their Monoamine Oxidase Inhibitor (MAOIs) drug candidates in the most advanced stage, i.e. preregistration include, Amgen.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Monoamine Oxidase Inhibitor (MAOIs) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Monoamine Oxidase Inhibitor (MAOIs): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Monoamine Oxidase Inhibitor (MAOIs) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Monoamine Oxidase Inhibitor (MAOIs) drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Monoamine Oxidase Inhibitor (MAOIs) R&D. The therapies under development are focused on novel approaches for Monoamine Oxidase Inhibitor (MAOIs).

Monoamine Oxidase Inhibitor (MAOIs) Report Insights

• Monoamine Oxidase Inhibitor (MAOIs) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Monoamine Oxidase Inhibitor (MAOIs) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Monoamine Oxidase Inhibitor (MAOIs) drugs?
• How many Monoamine Oxidase Inhibitor (MAOIs) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Monoamine Oxidase Inhibitor (MAOIs)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Monoamine Oxidase Inhibitor (MAOIs) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Monoamine Oxidase Inhibitor (MAOIs) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Avraham Pharmaceuticals
• PREXA SANTE
• Newron Pharmaceuticals
• Oryzon Genomics
• Ipsen
• Provepharm
• Roche
• Changzhou Si Yao Pharmaceutical

Key Products

• Ladostigil
• Methylthioninium chloride
• Safinamide
• Vafidemstat
• BN 82451
• ProvayBlue
• Sembragiline
• Rasagiline